{"status": "Ok", "redirect_url": "https://www.globenewswire.com/news-release/2026/04/20/3277010/0/en/Akari-Therapeutics-Reports-Positive-Preclinical-Data-for-AKTX-101-Demonstrating-Differentiated-Cytotoxicity-for-First-in-Class-TROP2-ADC-Payload-Targeting-RNA-Splicing.html", "message": "News view counter 671228 successfully enlarged"}